Sanofi: Oddo BHF still a buyer
(CercleFinance.com) - On Monday morning An Oddo BHF analyst confirmed a "Buy" rating on the share of Sanofi group, appreciating the clinical launch, in collaboration with GSK, of a candidate vaccine against Covid-19.
Phase I/II will recruit 440 participants from 11 sites in the US and will focus on assessing the safety of its candidate vaccine.
The broker said that this first step was expected, although confirms the timings previously announced by the companies. The current aim is to obtain its first clinical results in early December for a transition to phase III by the end of this year. If this schedule is respected, we could expect an approval in the first half of 2021 after an accelerated review, the broker says.
Oddo BHF therefore confirms its target price of 108 euros, meaning upside potential of 29%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Phase I/II will recruit 440 participants from 11 sites in the US and will focus on assessing the safety of its candidate vaccine.
The broker said that this first step was expected, although confirms the timings previously announced by the companies. The current aim is to obtain its first clinical results in early December for a transition to phase III by the end of this year. If this schedule is respected, we could expect an approval in the first half of 2021 after an accelerated review, the broker says.
Oddo BHF therefore confirms its target price of 108 euros, meaning upside potential of 29%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.